Explore 3 Stock Ideas & Industry Insights Download Free Report

Bone Biologics Corp Warrants

Company price
None USD 0.00(0%)
Last update at 2026-11-20T21:01:04.875245Z
Market Cap
0.00M

Momentum Score

…

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.72
Low
70.44
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-0.86
ROE
-119.03%
Net Debt
-3.03M
ROCE
-126.11%
Diluted EPS TTM
-0.14

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -1.48M -1.61M -1.82M -3.42M -4.43M
Net income 0.70M -1.61M -1.82M -3.42M -4.43M
Selling general administrative 2.09M 1.02M 0.48M 1.35M 2.69M
Gross profit 0.00M 0.00M 0.00M 0.00M 0.00M
Reconciled depreciation - - 0.00M 0.00M 0.00M
Ebit -3.67M - - -2.45M -2.38M
Ebitda -4.40M -1.10M -0.83M -2.45M -2.38M
Depreciation and amortization -0.73M - - 0.00M 0.00M
Operating income -3.67M -1.10M -0.83M -2.45M -2.79M
Other operating expenses 3.67M 1.10M 0.83M 2.45M 2.79M
Interest expense 2.18M 0.81M 1.00M 0.98M 1.23M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Net interest income -0.73M -0.81M -1.00M -0.98M -1.23M
Income tax expense -2.18M 0.00M 0.00M 0.00M 0.00M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 3.67M 1.10M 0.83M 2.45M 2.79M
Cost of revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total other income expense net 2.18M -0.51M -1.00M -0.98M -0.41M
Net income from continuing ops -1.48M -1.61M -1.82M -3.42M -4.43M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 3.74M 8.50M 6.68M 0.00M 0.03M
Other current assets 0.71M - - - 0.01M
Total liab 0.83M 2.55M 0.10M 13.69M 11.90M
Total stockholder equity 2.91M 5.95M 6.58M -13.69M -11.87M
Other current liab 0.47M 2.55M - 1.50M 0.54M
Common stock 0.00M 0.02M 0.01M 0.03M 0.03M
Capital stock 0.00M 0.02M 0.01M 0.03M 0.03M
Retained earnings -80.91M -71.96M -70.48M -68.86M -67.04M
Other assets - 0.00M - - -
Cash 3.03M 7.54M 6.68M 0.00M 0.02M
Total current liabilities 0.83M 2.55M 0.10M 13.69M 0.58M
Net debt -3.03M -7.54M -6.68M 11.72M 11.30M
Short term debt - - - 11.72M -
Short long term debt - - - 11.72M -
Short long term debt total - - - 11.72M 11.32M
Other stockholder equity 83.81M 77.89M 77.04M 55.14M 55.14M
Total current assets 3.74M 8.50M 6.68M 0.00M 0.03M
Net receivables 0.33M - - - -
Long term debt - - - - 11.32M
Inventory -0.33M - - - -
Accounts payable 0.36M 0.00M 0.10M 0.47M 0.04M
Non current assets total 0.00M 0.00M 0.00M 0.00M 0.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total cash from financing activities 4.43M 7.90M 0.40M 2.32M 4.37M
Net income -1.48M -1.61M -1.82M -3.42M -4.43M
Change in cash 0.86M 6.68M -0.02M -0.93M 0.27M
Begin period cash flow 6.68M 0.00M 0.02M 0.96M 0.69M
End period cash flow 7.54M 6.68M 0.00M 0.02M 0.96M
Total cash from operating activities -3.57M -1.23M -0.43M -3.25M -4.10M
Issuance of capital stock 4.43M 6.86M - 0.00M 4.37M
Depreciation - - 0.00M 0.00M 0.00M
Other cashflows from financing activities 4.43M 1.06M 0.40M 2.32M 0.60M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital -0.17M -0.32M 0.40M 0.14M 0.15M
Stock based compensation 0.27M 0.21M 0.06M 0.05M 0.52M
Other non cash items -2.18M 0.50M 0.94M 0.26M 0.38M
Free cash flow -3.57M -1.23M -0.43M -3.25M -4.10M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
ABT
Abbott Laboratories
-0.20
0.19%
103.00 25.97 17.24 3.57 3.20
MDT
Medtronic PLC
-0.59
0.59%
100.02 26.60 15.87 3.35 2.08
SYK
Stryker Corporation
-
-%
310.00 29.23 16.86 4.18 4.51
SEMHF
Siemens Healthineers AG
-
-%
48.34 39.57 21.32 3.01 3.29

Profile*

Bone Biologics Corp Warrants

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

2 Burlington Woods Drive, Burlington, MA, United States, 01803

781 552 4452

2

Name Title Year Born
Mr. Jeffrey Frelick CEO & President 1966
Ms. Deina H. Walsh Chief Financial Officer 1964
Dr. Shun'ichi Kuroda Co-Founder & Member of Scientific Advisory Board NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…